Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

Soria J.; Sequist L. V.; Goldman J. W.; Wakelee H. A.; Gadgeel S. M.; Varga A.; Yu H. A.; Solomon B. J.; Ou S. H.; Papadimitrakopoulou V.; Oxnard G. R.; Horn L.; Dziadziuszko R.; Chao B.; Spira A. I.; Liu S.; Mekhail T.; Matheny S.; Litten J.; Camidge R. D.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

【24h】

Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

机译：研究CO-1686-008的第2阶段中期结果：晚期非小细胞肺癌患者中不可逆，突变选择性EGFR抑制剂rociletinib（CO-1686）的1/2阶段研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2014年第6期|共1页
作者
Soria J.; Sequist L. V.; Goldman J. W.; Wakelee H. A.; Gadgeel S. M.; Varga A.; Yu H. A.; Solomon B. J.; Ou S. H.; Papadimitrakopoulou V.; Oxnard G. R.; Horn L.; Dziadziuszko R.; Chao B.; Spira A. I.; Liu S.; Mekhail T.; Matheny S.; Litten J.; Camidge R. D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
2. Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer [J] . Soria J., Sequist L. V., Goldman J. W., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：研究CO-1686-008的第2阶段中期结果：晚期非小细胞肺癌患者中不可逆，突变选择性EGFR抑制剂rociletinib（CO-1686）的1/2阶段研究
3. MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation [J] . Yi Long Wu, Qing Zhou, Xiaoqing Liu, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：MA16.06期I / II研究AC0010，突变选择性EGFR抑制剂，非小细胞肺癌（NSCLC）患者EGFR T790M突变患者
4. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study [J] . Sequist Lecia V, Han Ji-Youn, Ahn Myung-Ju, The lancet oncology . 2020,第3期

机译：Osimertinib加上EGFR突变阳性，达到的非小细胞肺癌患者的Savolitinib在EGFR酪氨酸激酶抑制剂上进行：临时结果，开放标签，阶段1B研究中的临时结果
5. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
6. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
7. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [O] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, 2007

机译：卡博替尼+厄洛替尼在晚期表皮生长因子受体（EGFR）-突变型非小细胞肺癌进展性疾病中进行表皮生长因子受体酪氨酸激酶抑制剂治疗的II期试验：加利福尼亚癌症协会II期试验（NCI 9303）
8. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study [O] . Filippo de Marinis, Konstantin K. Laktionov, Artem Poltoratskiy, 2021

机译：AFATINIB在EGFR TKI-NAINVE患者患有局部晚期或转移性EGFR突变阳性非小细胞肺癌：临时分析3B研究

Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

著录项

相似文献

相关主题

期刊订阅